{"entity":{"type":"insider","cik":"0001750698","url":"/insider/0001750698","json_url":"/insider/0001750698.json","name":"Vivo Capital IX, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":17,"n_filings":11,"first":"2020-07-21","last":"2023-08-10","span_basis":"filed_date"},"name_variants":[{"name":"Vivo Capital IX, LLC","source":"filing","n_filings":11,"first_seen":"2020-07-21","last_seen":"2023-08-10"}],"transactions":[{"id":7872555,"accession":"0001213900-23-065297","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-23-065297","line_url":"/filing/0001213900-23-065297#line-1","is_derivative":false,"issuer_cik":"0001728970","issuer_name":"IO Biotech, Inc.","issuer_ticker":"IOBT","issuer_name_source":null,"issuer_url":"/issuer/0001728970","owner_cik":null,"owner_name":"Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC; Vivo Capital Fund IX, L.P.; Vivo Capital IX, LLC","owner_display_name":"Vivo Opportunity Fund Holdings, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3157894.0,"shares_display":"3,157,894","price_per_share":1.9,"price_display":"1.90","price_state":"stated","total_value":5999998.6,"total_display":"5,999,998.60","total_whole":"5,999,999","shares_owned_after":3157894.0,"shares_owned_after_display":"3,157,894","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-08-09","filed_date":"2023-08-10","scope":"insider"},{"id":6257587,"accession":"0001213900-22-024317","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-22-024317","line_url":"/filing/0001213900-22-024317#line-1","is_derivative":false,"issuer_cik":"0001750117","issuer_name":"Tarsus Pharmaceuticals, Inc.","issuer_ticker":"TARS","issuer_name_source":null,"issuer_url":"/issuer/0001750117","owner_cik":null,"owner_name":"Vivo Capital Fund IX, L.P.; Vivo Capital IX, LLC","owner_display_name":"Vivo Capital Fund IX, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5374.0,"shares_display":"5,374","price_per_share":12.25,"price_display":"12.25","price_state":"stated","total_value":65831.5,"total_display":"65,831.50","total_whole":"65,832","shares_owned_after":2469001.0,"shares_owned_after_display":"2,469,001","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-05-05","filed_date":"2022-05-05","scope":"insider"},{"id":6156942,"accession":"0001213900-22-024052","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-22-024052","line_url":"/filing/0001213900-22-024052#line-3","is_derivative":false,"issuer_cik":"0001750117","issuer_name":"Tarsus Pharmaceuticals, Inc.","issuer_ticker":"TARS","issuer_name_source":null,"issuer_url":"/issuer/0001750117","owner_cik":null,"owner_name":"Vivo Capital IX, LLC; Vivo Capital Fund IX, L.P.","owner_display_name":"Vivo Capital IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19738.0,"shares_display":"19,738","price_per_share":12.67,"price_display":"12.67","price_state":"stated","total_value":250080.46,"total_display":"250,080.46","total_whole":"250,080","shares_owned_after":2474375.0,"shares_owned_after_display":"2,474,375","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-05-04","filed_date":"2022-05-04","scope":"insider"},{"id":6156939,"accession":"0001213900-22-024052","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-22-024052","line_url":"/filing/0001213900-22-024052#line-2","is_derivative":false,"issuer_cik":"0001750117","issuer_name":"Tarsus Pharmaceuticals, Inc.","issuer_ticker":"TARS","issuer_name_source":null,"issuer_url":"/issuer/0001750117","owner_cik":null,"owner_name":"Vivo Capital IX, LLC; Vivo Capital Fund IX, L.P.","owner_display_name":"Vivo Capital IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":451418.0,"shares_display":"451,418","price_per_share":13.25,"price_display":"13.25","price_state":"stated","total_value":5981288.5,"total_display":"5,981,288.50","total_whole":"5,981,289","shares_owned_after":2494113.0,"shares_owned_after_display":"2,494,113","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-05-03","filed_date":"2022-05-04","scope":"insider"},{"id":6156935,"accession":"0001213900-22-024052","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-22-024052","line_url":"/filing/0001213900-22-024052#line-1","is_derivative":false,"issuer_cik":"0001750117","issuer_name":"Tarsus Pharmaceuticals, Inc.","issuer_ticker":"TARS","issuer_name_source":null,"issuer_url":"/issuer/0001750117","owner_cik":null,"owner_name":"Vivo Capital IX, LLC; Vivo Capital Fund IX, L.P.","owner_display_name":"Vivo Capital IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":41800.0,"shares_display":"41,800","price_per_share":15.19,"price_display":"15.19","price_state":"stated","total_value":634942.0,"total_display":"634,942.00","total_whole":"634,942","shares_owned_after":2945531.0,"shares_owned_after_display":"2,945,531","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-05-02","filed_date":"2022-05-04","scope":"insider"},{"id":6789207,"accession":"0001213900-22-004647","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-22-004647","line_url":"/filing/0001213900-22-004647#line-1","is_derivative":false,"issuer_cik":"0001290149","issuer_name":"Sierra Oncology, Inc.","issuer_ticker":"SRRA","issuer_name_source":null,"issuer_url":"/issuer/0001290149","owner_cik":null,"owner_name":"Vivo Ventures Fund VII, L.P.; Vivo Opportunity, LLC; Vivo Opportunity Fund, L.P.; VIVO VENTURES VII, LLC; Vivo Ventures VII Affiliates Fund, L.P.; Vivo Capital Fund IX, L.P.; Vivo Capital IX, LLC","owner_display_name":"Vivo Ventures Fund VII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":800000.0,"shares_display":"800,000","price_per_share":27.0,"price_display":"27.00","price_state":"stated","total_value":21600000.0,"total_display":"21,600,000.00","total_whole":"21,600,000","shares_owned_after":2735853.0,"shares_owned_after_display":"2,735,853","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-31","filed_date":"2022-01-31","scope":"insider"},{"id":5379037,"accession":"0001140361-21-037658","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-21-037658","line_url":"/filing/0001140361-21-037658#line-2","is_derivative":false,"issuer_cik":"0001750117","issuer_name":"IO Biotech, Inc.","issuer_ticker":"IOBT","issuer_name_source":null,"issuer_url":"/issuer/0001750117","owner_cik":null,"owner_name":"Vivo Capital Fund IX, L.P.; Vivo Capital IX, LLC","owner_display_name":"Vivo Capital Fund IX, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":650000.0,"shares_display":"650,000","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":9100000.0,"total_display":"9,100,000.00","total_whole":"9,100,000","shares_owned_after":3015545.0,"shares_owned_after_display":"3,015,545","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-09","filed_date":"2021-11-12","scope":"insider"},{"id":5507846,"accession":"0001213900-21-034310","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-21-034310","line_url":"/filing/0001213900-21-034310#line-3","is_derivative":false,"issuer_cik":"0001750117","issuer_name":"Tarsus Pharmaceuticals, Inc.","issuer_ticker":"TARS","issuer_name_source":null,"issuer_url":"/issuer/0001750117","owner_cik":null,"owner_name":"Vivo Capital IX, LLC; Vivo Capital Fund IX, L.P.","owner_display_name":"Vivo Capital IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7704.0,"shares_display":"7,704","price_per_share":29.6,"price_display":"29.60","price_state":"stated","total_value":228038.4,"total_display":"228,038.40","total_whole":"228,038","shares_owned_after":2987331.0,"shares_owned_after_display":"2,987,331","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-25","filed_date":"2021-06-25","scope":"insider"},{"id":5507843,"accession":"0001213900-21-034310","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-21-034310","line_url":"/filing/0001213900-21-034310#line-2","is_derivative":false,"issuer_cik":"0001750117","issuer_name":"Tarsus Pharmaceuticals, Inc.","issuer_ticker":"TARS","issuer_name_source":null,"issuer_url":"/issuer/0001750117","owner_cik":null,"owner_name":"Vivo Capital IX, LLC; Vivo Capital Fund IX, L.P.","owner_display_name":"Vivo Capital IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":29.9,"price_display":"29.90","price_state":"stated","total_value":299000.0,"total_display":"299,000.00","total_whole":"299,000","shares_owned_after":2995035.0,"shares_owned_after_display":"2,995,035","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-24","filed_date":"2021-06-25","scope":"insider"},{"id":5507840,"accession":"0001213900-21-034310","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-21-034310","line_url":"/filing/0001213900-21-034310#line-1","is_derivative":false,"issuer_cik":"0001750117","issuer_name":"Tarsus Pharmaceuticals, Inc.","issuer_ticker":"TARS","issuer_name_source":null,"issuer_url":"/issuer/0001750117","owner_cik":null,"owner_name":"Vivo Capital IX, LLC; Vivo Capital Fund IX, L.P.","owner_display_name":"Vivo Capital IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37980.0,"shares_display":"37,980","price_per_share":29.8,"price_display":"29.80","price_state":"stated","total_value":1131804.0,"total_display":"1,131,804.00","total_whole":"1,131,804","shares_owned_after":3005035.0,"shares_owned_after_display":"3,005,035","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-23","filed_date":"2021-06-25","scope":"insider"},{"id":4959176,"accession":"0001213900-21-034298","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-21-034298","line_url":"/filing/0001213900-21-034298#line-2","is_derivative":false,"issuer_cik":"0001750117","issuer_name":"Tarsus Pharmaceuticals, Inc.","issuer_ticker":"TARS","issuer_name_source":null,"issuer_url":"/issuer/0001750117","owner_cik":null,"owner_name":"Vivo Capital IX, LLC; Vivo Capital Fund IX, L.P.","owner_display_name":"Vivo Capital IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":110000.0,"shares_display":"110,000","price_per_share":28.5,"price_display":"28.50","price_state":"stated","total_value":3135000.0,"total_display":"3,135,000.00","total_whole":"3,135,000","shares_owned_after":3043015.0,"shares_owned_after_display":"3,043,015","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-22","filed_date":"2021-06-25","scope":"insider"},{"id":4959172,"accession":"0001213900-21-034298","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-21-034298","line_url":"/filing/0001213900-21-034298#line-1","is_derivative":false,"issuer_cik":"0001750117","issuer_name":"Tarsus Pharmaceuticals, Inc.","issuer_ticker":"TARS","issuer_name_source":null,"issuer_url":"/issuer/0001750117","owner_cik":null,"owner_name":"Vivo Capital IX, LLC; Vivo Capital Fund IX, L.P.","owner_display_name":"Vivo Capital IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":91620.0,"shares_display":"91,620","price_per_share":29.7,"price_display":"29.70","price_state":"stated","total_value":2721114.0,"total_display":"2,721,114.00","total_whole":"2,721,114","shares_owned_after":3153015.0,"shares_owned_after_display":"3,153,015","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-21","filed_date":"2021-06-25","scope":"insider"},{"id":4494068,"accession":"0001213900-21-021965","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-21-021965","line_url":"/filing/0001213900-21-021965#line-1","is_derivative":false,"issuer_cik":"0001750117","issuer_name":"Tarsus Pharmaceuticals, Inc.","issuer_ticker":"TARS","issuer_name_source":null,"issuer_url":"/issuer/0001750117","owner_cik":null,"owner_name":"Vivo Capital IX, LLC; Vivo Capital Fund IX, L.P.","owner_display_name":"Vivo Capital IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":30.37,"price_display":"30.37","price_state":"stated","total_value":12148.0,"total_display":"12,148.00","total_whole":"12,148","shares_owned_after":3244635.0,"shares_owned_after_display":"3,244,635","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-14","filed_date":"2021-04-16","scope":"insider"},{"id":4092124,"accession":"0001209191-21-023066","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-023066","line_url":"/filing/0001209191-21-023066#line-3","is_derivative":false,"issuer_cik":"0001750117","issuer_name":"Instil Bio, Inc.","issuer_ticker":"TIL","issuer_name_source":null,"issuer_url":"/issuer/0001750117","owner_cik":null,"owner_name":"Vivo Capital IX, LLC; Vivo Capital Fund IX, L.P.","owner_display_name":"Vivo Capital IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300000.0,"shares_display":"300,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":6000000.0,"total_display":"6,000,000.00","total_whole":"6,000,000","shares_owned_after":12486787.0,"shares_owned_after_display":"12,486,787","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-23","filed_date":"2021-03-25","scope":"insider"},{"id":2516960,"accession":"0001209191-20-055423","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-055423","line_url":"/filing/0001209191-20-055423#line-3","is_derivative":false,"issuer_cik":"0001750117","issuer_name":"Tarsus Pharmaceuticals, Inc.","issuer_ticker":"TARS","issuer_name_source":null,"issuer_url":"/issuer/0001750117","owner_cik":null,"owner_name":"Vivo Capital Fund IX, L.P.; Vivo Capital IX, LLC","owner_display_name":"Vivo Capital Fund IX, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":4000000.0,"total_display":"4,000,000.00","total_whole":"4,000,000","shares_owned_after":3245035.0,"shares_owned_after_display":"3,245,035","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-20","filed_date":"2020-10-20","scope":"insider"},{"id":2857763,"accession":"0000899243-20-019915","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-019915","line_url":"/filing/0000899243-20-019915","is_derivative":false,"issuer_cik":"0001726403","issuer_name":"ALX ONCOLOGY HOLDINGS INC","issuer_ticker":"ALXO","issuer_name_source":null,"issuer_url":"/issuer/0001726403","owner_cik":null,"owner_name":"Vivo Opportunity, LLC; Vivo Capital Fund IX, L.P.; Vivo Opportunity Fund, L.P.; Vivo Capital IX, LLC","owner_display_name":"Vivo Opportunity, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":975000.0,"shares_display":"975,000","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":18525000.0,"total_display":"18,525,000.00","total_whole":"18,525,000","shares_owned_after":789474.0,"shares_owned_after_display":"789,474","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-21","filed_date":"2020-07-21","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001865494","name":"IO Biotech, Inc.","url":"/issuer/0001865494","role":"Ten percent owner","n_filings":2,"first_seen":"2021-11-12","last_seen":"2023-08-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001819790","name":"Tarsus Pharmaceuticals, Inc.","url":"/issuer/0001819790","role":"Ten percent owner","n_filings":6,"first_seen":"2020-10-20","last_seen":"2022-05-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001290149","name":"Sierra Oncology, Inc.","url":"/issuer/0001290149","role":"Ten percent owner","n_filings":1,"first_seen":"2022-01-31","last_seen":"2022-01-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001789769","name":"Instil Bio, Inc.","url":"/issuer/0001789769","role":"Ten percent owner","n_filings":1,"first_seen":"2021-03-25","last_seen":"2021-03-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001810182","name":"ALX ONCOLOGY HOLDINGS INC","url":"/issuer/0001810182","role":"Ten percent owner","n_filings":1,"first_seen":"2020-07-21","last_seen":"2020-07-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001750698","retrieved_at":"2026-08-22T22:59:42+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}